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Abstract
Background: A substantial proportion of the psychiatric burden of disease falls on the world's
poorest nations, yet relatively little is known about randomised trials conducted in these countries.
Our aim was to identify and describe a representative sample of mental health trials from low and
middle-income countries.
Methods: 6107 electronic records, most with full text copies, were available following extensive
searches for randomised or potentially randomised trials from low and middle-income countries
published in 1991, 1995 and 2000. These records were searched to identify studies relevant to
mental health. Data on study characteristics were extracted from the full text copies.
Results: Trials relevant to mental health were reported in only 3% of the records. 176 records
reporting 177 trials were identified: 25 were published in 1991, 45 in 1995, and 106 in 2000.
Participants from China were represented in 46% of trials described. 68% of trials had <100
participants. The method of sequence generation was described in less than 20% of reports and
adequate concealment of allocation was described in only 12% of reports. Participants were most
frequently adults with unipolar depression (36/177) or schizophrenia (36/177). 80% of studies
evaluated pharmacological interventions, a third of which were not listed by WHO as essential
drugs. 41% of reports were indexed on PubMed; this proportion decreased from 68% in 1991 to
32% in 2000.
Conclusion: In terms of overall health burden, trial research activity from low and middle-income
countries in mental health appears to be low, and in no area adequately reflects need.
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Background
Most of the global burden of mental illness falls to the
poorest nations, where 80% of world's population live
[1]. On average low and middle-income countries devote
less than 1% of their health expenditure to mental health
and have poorly developed mental health policies and
legislation. Treatment provision is often dismally under
resourced [2]. Randomised trials are the gold-standard for
evaluation of care, and systematic reviews of randomised
trials increasingly provide the basis for health care practice
and policy. Most trials, however, are conducted in high-
income countries [3]. The interventions assessed may be
unaffordable, unavailable or inappropriate for people in
other cultures and settings [4].
The extent to which interventions relevant to the preven-
tion and treatment of mental health problems in low and
middle-income countries have been evaluated locally is
unclear.
As part of an earlier project [5] bibliographic databases
were extensively searched to identify randomised, and
possibly randomised, trials with participants from low or
middle-income countries published during 1991, 1995 or
2000. The project presented here aimed to describe the
content and quality of mental health trials within this
dataset.
Methods
Search strategy
Detailed methods for this study have been published pre-
viously in this journal [6]. In brief, an earlier project
searched the Cochrane Library's Central Register of Con-
trolled Trials (CENTRAL) plus 25 biomedical biblio-
graphic databases to identify randomised or possibly
randomised trials from low and middle-income countries
published in 1991, 1995 or 2000. Countries were classi-
fied using World Bank definitions, categorizing by Gross
National Income per capita and by geographical region
[7]. For this paper, the electronic records of these initial
searches were searched again to identify studies relevant
to mental health. These records included titles, keywords,
and, where available, abstracts. Word roots based on
Mesh headings within "Mental Health" were utilised with
extra terms in Spanish, Portuguese and French. In addi-
tion, for 10% of the records not identified as being rele-
vant to mental health by the electronic search, full text
copies were checked to assess whether this was truly the
case. For each study identified as potentially relevant to
mental health, the author names were checked in PubMed
for additional citations from the three sample years
(1991, 1995 and 2000). Full text copies for all trials
potentially relevant to mental health were sought.
Assessment of studies for inclusion
The criteria used to assess eligibility were:
(i) Randomised or possibly randomised trials – this
included randomised trials, quasi randomised studies,
and controlled trials which could possibly be randomised.
(ii) Published in 1991, 1995 or 2000.
(iii) At least one participant from a low or middle-income
country as stated in the text, or if not stated this was
assumed if reports were from databases local to low and
middle-income countries and reported in local languages.
(iv) Participants were either people who had a mental
health problem, or they had been identified as being at
increased risk of developing a mental health problem.
Two authors (RJSS and MJ) independently assessed full
text copies of each record identified by the search. Dis-
crepancies were resolved by discussion.
Data extraction and data entry
Data on study quality and content were extracted onto a
specifically designed data extraction form. Each trial was
extracted onto a separate data extraction sheet. Hence, if
two trials were reported in the same paper, these were
extracted separately. For English language reports, data
were extracted by two people working independently. For
studies in other languages data were extracted twice for a
random sample of 10% of papers. Extraction was by
someone fluent in the relevant language. In the few cases
where full text was not available (n = 12), data were
extracted from the title plus abstract (n = 10), or title alone
if that was all that was available (n = 2).
Health conditions of participants in the trials were catego-
rised using the broad categories of the International Clas-
sification of Diseases tenth edition (ICD-10). The
interventions being evaluated were classified as drug,
physical non-drug, such as Electro-Convulsive Therapy
(ECT) or psychosocial. Drugs were further classified as to
whether they are listed on the WHO List of Essential Med-
icines [8]. Outcomes were classified using a system devel-
oped for a survey of trials of schizophrenia [9].
Data were entered into Meerkat software [10] and com-
pared. For each variable, 80% agreement was considered
acceptable. If the agreement fell below this, possible rea-
sons were investigated and data re-extracted. To assess
accessibility, each citation was searched for on PubMed in
August 2006 using author AND year or failing this title.BMC Psychiatry 2008, 8:69 http://www.biomedcentral.com/1471-244X/8/69
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Statistical analyses
Characteristics of the trials in terms of where they were
conducted, the language of report, health problems being
addressed, interventions and outcomes were described.
Frequencies were compared using χ2 for linear trend. Top-
ics covered by the trials were compared, by region, with
the WHO revised 2002 burden of disease estimates [11].
Global burden of disease estimates for mortality and YLD
(years lost to disability) are available for both economic
groups (high, upper middle, lower middle and low) and
broad geographic regions [12]. These estimates are further
categorised by cause e.g. unipolar depression. We calcu-
lated an estimate of how trial-based research activity
reflects burden of disease as a 'research: need' ratio, by
dividing the number of people randomised with each cat-
egory of mental health problem by the WHO's Years Lost
due to Disability (YLD) for the same category. The find-
ings were compared with each other in order to investigate
which disorders and populations are the focus of a rela-
tively high or low research activity.
Results
Of the 5838 records not identified as being potentially rel-
evant to mental health by electronic searching, full reports
of 587 records in English, 380 in Spanish or Portuguese
and 144 in Russian, Ukrainian or Romanian were hand
searched to check if this was truly the case. An extra three
reports were identified as being potentially relevant to
mental health and subject to independent eligibility
assessment. Only one of the three studies was deemed eli-
gible for inclusion in this survey.
Of the 6107 reports of randomised or possibly ran-
domised studies with participants in low and middle-
income countries, and published in the years 1991, 1995,
and 2000, 176 (3%) were relevant to mental health.
Of the 176 records, 167 represented full reports in a jour-
nal; for five of these we had access to the abstract only.
Two of the full journal reports described multiple trials:
for one of these reports only one trial was relevant to men-
tal health, for the other report two trials were relevant. Of
the other records; two were conference abstracts, one was
a conference proceeding, three were journal letters and
one was a thesis. For a further two citations, only the title
was available.
As one report described two trials, 177 studies are
included in the analyses presented here. Of these, a full
text report was available for 165 (93%). Agreement for
data extraction exceeded 80% for all items.
The number of reports increased across time with 25 in
1991, 45 in 1995, and 107 in 2000. Overall, 85% of the
reports were written in either English (80/177) or Manda-
rin Chinese (71/177). The proportion of reports written in
Chinese increased from a quarter (7/25) to a half (53/
107) over the sample period. The languages of the remain-
ing 15% of reports in descending order of frequency were
Spanish, Russian, Portuguese, Korean, Polish and Serbo-
Croatian. For one citation for which we had only obtained
the title the language of the full report remains unknown.
A quarter of the trials recruited from low-income coun-
tries (41/177) (Figure 1). China was the country of recruit-
ment for 46% of the studies (81/177); it was a low-
income country in 1991 and 1995, but had become lower
middle-income in 2000. Seven trials recruited from more
than one country, with two including a high-income
nation. Two thirds of the trials (118/177) had less than
100 participants, 30% (52/177) randomised 100–499
people and 3 studies had more than 500 participants. The
proportion of studies with less than 100 participants did
not change substantively across time. Setting for the study
could be determined from the report for 82/177 studies
(46%). Of these, 68 were urban, 7 were rural and 7 were
both. The site of recruitment was not clear for 41/177
studies (23%). Of the 136 reports with relevant informa-
tion on site, this was a hospital for 82% (111/136), in the
community for 8% (11/136), in an educational institu-
tion for 5% (7/136), in primary care for 1% (2/136), and
in a variety of other sites for 4% (5/136).
Study quality and funding
Adequate allocation concealment was described for 12%
of studies (21/177), and method of sequence generation
was stated for 17% (30/177). For 62% of studies (109/
177) there was information about blinding of the inter-
vention; 77/109 were reported to have been double blind.
One in five reports mentioned an ethics committee (34/
177), and a third mentioned consent (61/177). A source
of funding was mentioned for 25% of studies (45/177).
Participants
People aged 18–60 years were included in 79% of the
studies (135/177). Of these, 39 also included participants
who were over 60 years, and 12 also included those who
were younger than 18 years. Seven studies included only
people aged more than 60 years, and 22 included only
people younger than 18 years. Age of the participants was
not clear in 13 trials (7%). People of both sexes were
recruited to three quarters of the trials (135/177). Partici-
pants were male only for 19 studies and female only for 7.
Gender of participants was not clear for 25 reports (15%).
The most common health problems for participants in the
studies were unipolar depression, (36/177) and schizo-
phrenia (36/177) (Table 1). Three trials (1%) addressed
prevention rather than treatment.BMC Psychiatry 2008, 8:69 http://www.biomedcentral.com/1471-244X/8/69
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Interventions and outcomes
Most studies (80%) evaluated pharmacological interven-
tions (Table 2); a third of these drugs (47/140) were listed
by WHO as essential drugs.
Mental state was the most common outcome, reported by
three quarters of studies (129/177) (Table 3). Less than
half the studies reported adverse effects (78/177). For
83% of studies (147/177) at least one scale was used to
rate outcome (median = 1, range = 1–6). The most fre-
quently reported scales were Hamilton rating scale for
depression (HAM-D) (24/177), and the Hamilton Anxi-
ety Scale (HAM-A) (18/177). Nine reports did not include
data on outcome.
Number of trials by country (totals for sample period) Figure 1
Number of trials by country (totals for sample period).
Table 1: Mental health problems assessed, by year of publication
Mental Health Problem 1991 1995 2000 Total
n = 25 (%) n = 45 (%) N = 107 (%) N = 177 (%)
Unipolar depression 6 (24) 3 (7) 27* (25) 36 (20)
Schizophrenia 6 (24) 9 (20) 21 (20) 36 (20)
Other anxiety disorders 3 (12) 3 (7) 14 (13) 19 (11)
Alzheimer's and other dementias 3 (12) 4 (9) 12* (11) 19 (11)
Disorders associated with brain damage/dysfunction - 9 (20) 5 (5) 14 (8)
Drug use disorders 2 (8) 3 (7) 8 (7) 13 (7)
Bipolar depression - 4 (9) 5 (5) 9 (5)
Psycho sexual disorders 2 (8) 1 (2) 5 (5) 8 (5)
Alcohol use disorders 2 (8) 4 (9) 1 (<1) 7 (4)
Panic disorder - 1 (2) 5 (5) 6 (3)
Obsessive Compulsive Disorder - 1 (2) 2 (2) 3 (2)
Non organic enuresis 1 (4) 1 (2) - 2 (1)
Non organic sleep disorders - 1 (2) 1 (<1) 2 (1)
Somatoform disorders 1 (2) 1 (<1)
Conduct disorder - - 1 (<1) 1 (<1)
* includes prevention trialsBMC Psychiatry 2008, 8:69 http://www.biomedcentral.com/1471-244X/8/69
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Accessibility
Overall, 41% of the reports could be identified on
PubMed when searched in August 2006 (73/177). The
proportion identified decreased from 68% in 1991 to
34% in 2000 (χ2 for linear trend 10.92, 1 df, p = 0.001).
Of the 80 reports in English, 54 (68%) were identified in
PubMed, compared with nine (13%) of the 71 reports in
Chinese. The proportion of Chinese reports identified on
PubMed decreased from (6/7) 86% in 1991 to (2/53) 3%
in 2000. In total 10 (40%) of the 25 reports in other lan-
guages were identified in MEDLINE. 66% (117/177) of
citations were identified on Cochrane's CENTRAL during
the original search, again the proportion located dropped
from 80% in 1991 to 57% in 2000.
Ratio of trial-based research activity to burden of disease
Unipolar depressive disorders and schizophrenia have the
highest burden of disease as assessed by years lost due to
disability (Table 4). However, more people with drug use
disorders were randomised per year lost due to disability
than any other type of mental health disorder.
Discussion
Over the decade included in our sample, only 3% of trials
from low and middle-income countries focused on men-
tal health problems. The quality of reporting of study
design was poor, with the procedures used for randomisa-
tion and concealment of allocation being described for
less than one fifth. Inadequate reporting of the methodo-
logical quality of trials relevant to mental health is, how-
ever, also common for studies conducted in Europe and in
North America [9]. Even in high impact general journals,
40% of studies fail to describe the procedures used for ran-
domisation [13]. Two thirds of the studies in our sample
mentioned blinding of the intervention, although we did
not attempt to assess the adequacy or completeness of this
information. It seems unlikely that many were adequately
Table 2: Types of intervention trial and year of publication
Type of trial 1991 1995 2000 Total
n = 25 (%) n = 45 (%) n = 107 (%) n = 177 (%)
Drug vs drug 13 (52) 20 (44) 56 (52) 89 (50)
Drug vs non-active (eg placebo) 4 (16) 9 (20) 20 (19) 33 (19)
Drug vs psychosocial - - 7 (7) 7 (4)
Drug vs biological non-drug (eg ECT) 2 (8) 2 (4) 2 (2) 6 (3)
Drug vs mixed (eg placebo AND psychotherapy) - - 1 (<1) 1 (<1)
Drug dose finding 1 (4) 2 (4) 1 (<1) 4 (2)
Total trials involving drugs 20 (80) 33 (73) 87 (81) 140 (80)
Biological non-drug vs biological non-drug 1 (4) 2 (4) 3 (3) 6 (3)
Psychosocial vs psychosocial 4 (16) 4 (9) 5 (5) 13 (7)
Psychosocial vs non-active 3 (7) 8 (7) 11 (6)
Biological non-drug vs non-active 1 (2) 3 (5) 4 (2)
ECT = electroconvulsive therapy
Table 3: Types of outcome reported, by year of publication
Outcome 1991 1995 2000 Total (%) Number of different scales
n = 25 n = 45 n = 107 n = 177
Mental state 12 26 91 129 (73) 26
Physiological assessment 5 24 52 81 (46) 15
Adverse effects 4 19 55 78 (44) 5
Global impression 5 9 28 42 (24) 6
Cognitive functioning 6 11 21 38 (21) 7
Withdrawal and craving - 3 9 12 (7) 3
Psychological tests 1 6 2 9 (5) 8
Social functioning - 3 5 8 (5) 4
Behaviour - 1 7 8 (5) 1
Development and learning 3 3 6 (4) 1
Compliance/attitudes to treatment 1 - 3 4 (2) 2
Quality of life - - 2 2 (1) 1
Economic 1 - - 1 (1) -
Use of health service resources - - - --
Studies reported more than one type of outcomeBMC Psychiatry 2008, 8:69 http://www.biomedcentral.com/1471-244X/8/69
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blinded, as, in trials for people with schizophrenia, just
over one fifth have adequate descriptions [9].
Size
Most trials were small and few involved more than one
country. The value of international trials has been demon-
strated in cancer, heart disease and perinatal care; such
studies enable large numbers to be recruited [14], ensure
wide generalisability of results [15] and facilitate research
capacity building [16]. Conducting large international tri-
als in mental health would be likely to have similar
advantages.
Content
Participants in the trials reported here had a wide range of
mental health problems, but the most common were
depression and schizophrenia. Overall, 80% of the studies
evaluated the effects of one or more drugs. This is the
same level as for trials of schizophrenia overall [9], and
hence may reflect a greater acceptance of quantitative eval-
uation for drugs as compared to other forms of therapy
within mental health. The low level of community based
and prevention studies highlights a major gap for future
research. Such trials should be a priority.
Outcomes
Most studies reported using scales to assess outcomes.
Nevertheless, interpretation of scales can be difficult and
they are rarely used in clinical care. It would therefore be
more relevant for trials to report outcome measures that
have more intuitive meaning to patients, their families,
and clinicians. It would seem a shame for those rare trial-
ists in low and middle-income countries to dissipate their
energies recording outcomes that are difficult to use in
everyday practice.
Reporting
The low level of reporting on how the study was funded is
not uncommon. For example, funding source was
reported for 39% to 51% of surgical trials [17,18]. Simi-
larly, many studies describing the quality of randomised
trials do not report on whether ethics approval and con-
sent are explicitly mentioned.
The CONSORT (Consolidated Standards of Reporting Tri-
als) statement of 1996 [19], updated in 2001 [20] gives
recommendations for how to report randomised trials
using a 22 item checklist. Some journals have adopted
CONSORT; although this endorsement is associated with
improved reporting of randomised trials, reporting is
often still not adequate [13,21]. Considerable scope
remains for improving the reporting of randomised trials.
In 2003, only 22% of high impact general and internal
medicine journals mentioned CONSORT in their instruc-
tions for authors, and many used ambiguous language
regarding what was expected from authors [22]. Neverthe-
less, as funding source, ethics approval and consent are
not included in the CONSORT checklist, the quality of
reporting for these items may not improve unless
researchers are made more aware of their relevance.
Geographical Variation
The proportion of trials from different geographic regions
varied greatly; for example only three trials were identified
from the Middle East or North Africa region (comprised of
Algeria, Djibouti, Egypt, Iran, Iraq, Jordan, Lebanon, Lib-
yan Arab Jamahiriya, Malta, Morocco, Occupied Palestin-
ian Territory, Oman, Saudi Arabia, Syrian Arab Republic,
Tunisia and Yemen). In this largely Arabic speaking part of
the world, with a population of 300 million people, men-
tal health literature may be not be easily accessible by
searching in English, and many journals are not indexed
on any database [23]. Nevertheless, despite searching Afri-
can, Arab, Iranian and several Egyptian and Eastern Med-
iterranean biomedical databases, only three studies were
identified. The religious and cultural individuality of this
region, along with the presence of conflict, could make
evaluative mental health research enormously difficult.
Table 4: Research:need ratios for all sample years
Mental health problem Number of trials Number of participants WHO YLD 2002 Ratio
Unipolar depressive disorders 36 2913 56484904 5.16
Schizophrenia 33 5270 14353406 36.72
Alcohol use disorders 7 434 13646427 3.18
Bipolar disorder 9 805 12472021 6.45
Panic disorder 6 272 5996378 4.54
Dementias 19 1418 5421155 26.20
Obsessive-compulsive disorder 3 202 4364394 4.63
Drug use disorders 13 5749 4064053 141.40
Post traumatic stress disorder 0 0 2842102 -----
Mental Health Problems were sorted by WHO YLD 2002
Ratio = Number randomised/YLD need (×10*6)BMC Psychiatry 2008, 8:69 http://www.biomedcentral.com/1471-244X/8/69
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In contrast, China produced almost half (46%) of all trials
in mental health, and accounted for most of the increase
in annual output across the decade 1991 to 2000.
Although the number of mental health trials does seem to
be linked to national wealth [24], the increased trial activ-
ity in China is unlikely to be driven by income alone. With
rapidly increasing numbers of trials there has been con-
cern about the quality of randomised trial conducted in
China [25]. Evidence of similar trends [26] are beginning
to happen in randomised trials of traditional Chinese
medicine which have increased in both quality and qual-
ity since 2000 [27].
Since 2001 it appears that China continues to be domi-
nant in its production of mental health trials as evidenced
in a recent review of mental health trials from low and
middle-income countries where two thirds of trials con-
ducted in low and middle-income countries were from
China [28]. This review differs from our survey in that it
covers a different time period and has a narrower range of
interest concentrating on interventions for schizophrenia,
depression, developmental disability and alcohol
dependence.
Accessibility
Forty five percent of these reports were in English. 'Posi-
tive' trial reports are more likely to be published in Eng-
lish than in other languages [29]. Less than half of these
studies from low and middle-income countries were cited
on PubMed; even for reports in English one third were not
available in PubMed. Research from low and middle-
income countries is therefore underrepresented [30,31].
Proportions of these trials accessible through Cochrane's
CENTRAL register are somewhat better. Although CEN-
TRAL is the most comprehensive database of randomised
trials, one third of these mental health studies were not
available on it.
Although the number of trials conducted in each year is
increasing across time, accessibility of their citations on
bibliographic databases, such as PubMed, seems to be
decreasing. The time difference from publication to our
assessment of accessibility was greatest for studies from
1991, nevertheless this seems unlikely to explain the
decline in accessibility within PubMed over time, as by
2006 studies published in 2000 should have been
indexed and available. The lack of availability on
MEDLINE of trials reported in Chinese along with the
large increase in trials originating in China seems an
important factor. Indexing has been found to be poor
with only 95 of the total 4 959 journals which are listed in
MEDLINE being published in China [32]. Reports of ran-
domised trials are not always easy to identify, and efforts
by institutions such as the Cochrane Collaboration and
WHO to make them more accessible should continue.
Comparison with burden of disease
Using the crude estimates within our sample, more people
with 'drug use disorders' (other than alcohol misuse) have
been randomised per year-lost-though-disability in low
and middle-income countries than people in the other
categories of mental health problems. This may reflect the
greater availability of funding for research relevant to hep-
atitis or HIV/AIDS, compared with other mental health
problems such as schizophrenia, dementia, affective or
anxiety-linked problems, alcohol related difficulties and
psychological trauma.
Suggestions to improve relevance, standards and reporting 
of trials from low and middle-income countries
Accessibility to trials conducted in low and middle-
income countries should be improved by prospective reg-
istration of all future trials, as endorsed by the Interna-
tional Committee of Medical Journal Editors (ICMJE) and
the World Health Organization's International Clinical
Trials Registry Platform (WHO-ICTRP) [33,34]. China,
India and Sri Lanka now have national trial registries that
form part of the WHO-ICTRP network of Primary Regis-
ters [34]. Registers in Latin America and Africa are also
preparing to meet international requirements for trial reg-
istration [35,36]. Prospective registration as a pre-requi-
site to publication is also beginning to receive local
support from medical journal editors [37].
In addition to improving the accessibility of trial reports
prospective registration of trials could also improve the
internal validity of trials. By encouraging reporting of ele-
ments identified in the CONSORT statement in trial pro-
tocols (method of randomization, allocation
concealment, blinding and attrition) trial design will be
optimised during the planning of trials [38]. Trial registra-
tion is also being used in some countries to improve the
planning and reporting of ethical considerations such as
informed consent, funding sources and ethics committee
approval [39].
We would also suggest that coordinated action is required
from medical journal editors in low and middle-income
countries to adhere to the ICMJE uniform requirements
for submitting final reports for trials [40]. This would
require details of ethics committees, informed consent
and funding sources in addition to the use of CONSORT
checklists and flow diagrams. Provision of clear instruc-
tions to authors regarding CONSORT and ICMJE require-
ments and appropriate checklists, education of peer
reviewers, and journal policies that consistently preclude
publication of trials that do not meet these requirements
are also suggested [41].
Initiatives to provide training for ethics committees,
researchers, investigators, regulators and students haveBMC Psychiatry 2008, 8:69 http://www.biomedcentral.com/1471-244X/8/69
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commenced in some parts of the developing world as a
crucial first step in building capacity for ethically sound
research [42,43]. However, local and regional regulatory
frameworks and legislation are also needed to interpret
international guidelines on the standards of care in the
context of local constraints.
Strengths
Strengths of our study are that we utilised comprehensive
and extensive electronic searches of not only the Cochrane
Library's CENTRAL, but also of biomedical bibliographic
databases from low and middle-income countries. Full
text copies were available for a high proportion of cita-
tions. Previous surveys of mental health research from low
and middle-income countries have either concentrated on
particular regions or have investigated only selected jour-
nals or individual databases [30,31].
Weaknesses
Despite the extensive searches, it is likely that we failed to
identify some relevant studies. Due to time constraints,
we were not able to search all the bibliographic databases
which include journals from low and middle-income
countries, and new databases have become available since
our searches were completed. Other factors are that poor
indexing within some databases may have impaired
retrieval, and some journals may not be indexed or only
partially indexed.
Conclusion
What this paper adds
￿ The enormous disparity between mental health evalua-
tive research and other areas of medicine
￿ The emergence of China as a force in this area
￿ Pioneers are increasingly undertaking research in situa-
tions of great constraint
￿ The increasing difficulty in identifying this work
In terms of overall health burden, trial research activity
from low and middle-income countries in mental health
appears to be low, and in no area adequately reflects need.
Pragmatic randomized trials in mental health addressing
locally relevant issues, conducted during routine clinical
practice, free of industry sponsorship and using simple,
clinically relevant outcomes are emerging from low and
middle-income countries [44,45]. However, the results of
this survey suggest that studies of population-based, non-
drug interventions and those evaluating prevention and
effective service delivery are needed. Research conducted
in low and middle-income countries should be accessible
and address questions of relevance to local health needs
and use outcomes that are useful to patients, carers and
clinicians based in those countries.
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